| Title | Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis |
|---|---|
| Author | Ji-Chan Jang1,2, Yong-Gyun Jung3,4,5, Jungil Choi6, Hyunju Jung7, and Sungweon Ryoo7,8* |
| Address | 1Molecular Mechanisms of Antibiotics, Division of Life Science, 2Research Institute of Life Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea, 3Interdisciplinary Program of Biomodulation, College of Natural Science, 4Myongji Bioefficiency Research Centre, 5Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin 17058, Republic of Korea, 6Department of Materials Science and Engineering Northwestern University Evanston, IL 60208, USA, 7Korean Institute of Tuberculosis, Osong 28158, Republic of Korea, 8Korean National Tuberculosis Association, Seoul 06763, Republic of Korea |
| Bibliography | Journal of Microbiology, 55(6),483-487, 2017, |
| DOI | 10.1007/s12275-017-6630-1 |
| Key Words | bedaquiline, Mycobacterium tuberculosis, totally drug resistant Mycobacterium tuberculosis |
| Abstract | This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc agarose channel (DAC) system. Time-lapse images of single bacterial cells under culture conditions with different concentrations of bedaquiline were analysed by image processing software to determine minimum inhibitory concentrations (MICs). Bedaquiline inhibited the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L. The results of the present study demonstrate that bedaquiline, newly approved by the United States Food and Drug Admi-nistration (FDA), may offer therapeutic solutions for TDR -TB. |